These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35661226)

  • 1. Two-stage screened selection designs for randomized phase II trials with time-to-event endpoints.
    Wu J; Pan H; Hsu CW
    Biom J; 2022 Oct; 64(7):1207-1218. PubMed ID: 35661226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screened selection design for randomised phase II oncology trials: an example in chronic lymphocytic leukaemia.
    Yap C; Pettitt A; Billingham L
    BMC Med Res Methodol; 2013 Jul; 13():87. PubMed ID: 23819695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sample size computation in phase II designs combining the A'Hern design and the Sargent and Goldberg design.
    Neven A; Mauer M; Hasan B; Sylvester R; Collette L
    J Biopharm Stat; 2020 Mar; 30(2):305-321. PubMed ID: 31331234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase II selection design with order constrained strata.
    Chen Y; Yu M
    Biometrics; 2024 Jan; 80(1):. PubMed ID: 38364810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.
    Tang H; Foster NR; Grothey A; Ansell SM; Goldberg RM; Sargent DJ
    J Clin Oncol; 2010 Apr; 28(11):1936-41. PubMed ID: 20212253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advantages of multi-arm non-randomised sequentially allocated cohort designs for Phase II oncology trials.
    Mossop H; Grayling MJ; Gallagher FA; Welsh SJ; Stewart GD; Wason JMS
    Br J Cancer; 2022 Feb; 126(2):204-210. PubMed ID: 34750494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian single-to-double arm transition design using both short-term and long-term endpoints.
    Xu T; Shi H; Lin R
    Pharm Stat; 2023; 22(4):588-604. PubMed ID: 36755420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-arm Phase II cancer survival trial designs.
    Wu J
    J Biopharm Stat; 2016; 26(4):644-56. PubMed ID: 26098141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adaptive clinical trial designs with blinded selection of binary composite endpoints and sample size reassessment.
    Roig MB; Melis GG; Posch M; Koenig F
    Biostatistics; 2023 Dec; 25(1):237-252. PubMed ID: 36150142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practical and robust test for comparing binomial proportions in the randomized phase II setting.
    Attwood K; Park S; Hutson AD
    Pharm Stat; 2022 Mar; 21(2):361-371. PubMed ID: 34626075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosis.
    Bratton DJ; Phillips PP; Parmar MK
    BMC Med Res Methodol; 2013 Nov; 13():139. PubMed ID: 24229079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A stratified adaptive two-stage design with co-primary endpoints for phase II clinical oncology trials.
    Cabarrou B; Leconte E; Sfumato P; Boher JM; Filleron T
    BMC Med Res Methodol; 2022 Oct; 22(1):278. PubMed ID: 36289451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian single-arm phase II trial designs with time-to-event endpoints.
    Wu J; Pan H; Hsu CW
    Pharm Stat; 2021 Nov; 20(6):1235-1248. PubMed ID: 34085764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mixed response and time-to-event endpoints for multistage single-arm phase II design.
    Lai X; Zee BC
    Trials; 2015 Jun; 16():250. PubMed ID: 26037094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit.
    Royston P; Barthel FM; Parmar MK; Choodari-Oskooei B; Isham V
    Trials; 2011 Mar; 12():81. PubMed ID: 21418571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design.
    Richert L; Doussau A; Lelièvre JD; Arnold V; Rieux V; Bouakane A; Lévy Y; Chêne G; Thiébaut R;
    Trials; 2014 Feb; 15():68. PubMed ID: 24571662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II clinical trials with time-to-event endpoints: optimal two-stage designs with one-sample log-rank test.
    Kwak M; Jung SH
    Stat Med; 2014 May; 33(12):2004-16. PubMed ID: 24338995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. To randomize, or not to randomize, that is the question: using data from prior clinical trials to guide future designs.
    Vanderbeek AM; Ventz S; Rahman R; Fell G; Cloughesy TF; Wen PY; Trippa L; Alexander BM
    Neuro Oncol; 2019 Oct; 21(10):1239-1249. PubMed ID: 31155679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adaptive multiarm multistage clinical trials.
    Ghosh P; Liu L; Mehta C
    Stat Med; 2020 Apr; 39(8):1084-1102. PubMed ID: 32048313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design issues of randomized phase II trials and a proposal for phase II screening trials.
    Rubinstein LV; Korn EL; Freidlin B; Hunsberger S; Ivy SP; Smith MA
    J Clin Oncol; 2005 Oct; 23(28):7199-206. PubMed ID: 16192604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.